Hims & Hers Health, Inc. (NYSE:HIMS) is one of the 10 Stocks Leave Wall Street Stunned. Hims & Hers extended its rally for ...

San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with ...

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 12.1% in the afternoon session after the company's CEO ...

Hims & Hers (NYSE: HIMS) is attracting investors looking to buy the dip in this impressive growth stock. Where to invest ...

As GLP-1 drugs like Wegovy and Ozempic grow in popularity, so too has a kind of alternative: compounded versions of the drugs ...

The Danish pharmaceutical said it was ending the partnership because Hims is selling and promoting a cheaper copycat of its ...

Hims & Hers Health Inc. (NYSE: HIMS) shares are trading higher Thursday. The stock appears to be bouncing back a bit after ...

The stock's market-beating momentum has come crashing to a halt, following shocking allegations from one of the world's largest pharmaceutical companies.

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top ...

Novo Nordisk ended a short-lived agreement to sell its Wegovy weight-loss drug through Hims & Hers Health on Monday, sending ...

Earlier this week, the pharma giant publicly accused Hims & Hers of “deceptive” marketing that is putting patient safety at risk.

Investing.com -- Hims & Hers Health (NYSE: HIMS) has named Dheerja Kaur as its first-ever Chief Product Officer, according to an announcement from CEO Andrew Dudum.